Clinical trials: Disabilities, Intellectual
Child Behavior Problem, Intellectual Disability
Determining the Effectiveness of Sexual Health and Development Education for Children With Intellectual Disability
By integrating sexuality and disability literatures, theories, and research, this study aims to: determine the effectiveness of sexual health and development education for children (12-18 years) with mild to moderate intellectual…
- Conditions
- Child Behavior Problem, Intellectual Disability, Sexuality
- Trial name
- NCT04635969
- Testing
- Sexual Health and Development Education for Children With Intellectual Disability
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Aylin KURT
Mucopolysaccharidosis II
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
- Trial name
- NCT04573023
- Testing
- JR-141, Idursulfase, JR-141 or Idursulfase
- Where
- 26 sites in United States, Argentina and 10 more
- Volunteers
- 86 people
- Sponsor
- JCR Pharmaceuticals Co., Ltd.
Intellectual Disability
Effects of Adaptive Physical Activity on Health-related Fitness of Students With Intellectual Disabilitiesdisability
The object of this study is the theory and practice of adaptive physical activity for people with intellectual disability. It focuses on the concepts, paths, and applications of adaptive physical activities for young people with…
- Trial name
- NCT06444659
- Testing
- Adaptive Physical Activity Classes
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hunan Normal University
Intellectual and Developmental Disability
Community Mobility Plans: Improving Community Participation Through Travel Interventions for Adolescents and Young Adults With Intellectual and Developmental Disabilities
The goal of this study is to establish a proof-of-product by evaluating and refining the "Community Mobility Planning Process" curriculum activities with adolescents and young adults (AYA; ages 16-25 years) with Intellectual…
- Trial name
- NCT07401563
- Testing
- Community Mobility Planning Process (CMPP)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Temple University
Fragile X Syndrome
A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
This study is a multisite, randomized, double-blind, placebo-controlled, phase 2 study of MG01CI (low dose and high dose once daily) for 6 weeks compared with placebo in a 1:1 ratio of 60 adolescent and adult subjects with…
- Trial name
- NCT02126995
- Testing
- MG01CI extended-release tablet
- Where
- 12 sites in United States, Israel
- Volunteers
- 62 people
- Sponsor
- Alcobra Ltd.
Fragile X Syndrome
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)
The aim of this study is to characterize the pharmacokinetics and safety/tolerability of AFQ056 in children with Fragile X Syndrome(FXS)
- Trial name
- NCT01482143
- Testing
- AFQ056
- Where
- 4 sites in United States, Spain
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Prader-Willi Syndrome, Hyperphagia
Fiber Intervention on Gut Microbiota in Children With Prader-Willi Syndrome
Prader-Willi syndrome (PWS) is the most common syndromic cause of obesity. Individuals with PWS characteristically experience excessive weight gain and severe hyperphagia with food compulsivity in early childhood, which often…
- Trial name
- NCT04150991
- Testing
- Fiber intervention
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University of Alberta
Down Syndrome (DS), Balance Assessment
Effects of a Structured Physical Activity Program on Balance and Functional Performance in Children With Down Syndrome
Children with Down syndrome commonly exhibit hypotonia, impaired balance, and reduced functional mobility. This study aimed to evaluate the effects of a structured yoga-based physical activity program on balance and functional…
- Conditions
- Down Syndrome (DS), Balance Assessment, Physical Activities, Yoga
- Trial name
- DS-YOGA (NCT07534085)
- Testing
- Yoga Program
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Ankara University
Fragile X Syndrome (FXS)
A Study of OV101 in Individuals With Fragile X Syndrome
The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.
- Trial name
- ROCKET (NCT03697161)
- Testing
- OV101 (gaboxadol)
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ovid Therapeutics Inc.
Down Syndrome
Role of Early Motor Experience in Infants With Down Syndrome
Infants with Down syndrome show significant delays and weaknesses in motor, cognitive, and language development compared to typically developing infants.
- Trial name
- NCT05144373
- Testing
- Gross motor intervention, gross and fine motor intervention
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Georgia State University
Fragile X Syndrome
Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome
The purpose of this study is to determine whether Lovastatin, Minocycline and the combination Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X individuals.
- Trial name
- LovaMiX (NCT02680379)
- Testing
- Minocycline, then Minocycline/Lovastatin, Lovastatin, then Minocycline/Lovastatin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Université de Sherbrooke
Prader-Willi Syndrome
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management.
- Trial name
- NCT05322096
- Testing
- RGH-706
- Where
- 23 sites in United States, Czechia and 3 more
- Volunteers
- 39 people
- Sponsor
- Gedeon Richter Plc.
Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia
Palliative Care Needs of Children With Rare Diseases and Their Families
The palliative care needs of family caregivers of children with rare diseases and their children are largely unmet, including the need for support to prepare for future medical decision making.
- Conditions
- Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome
- Trial name
- FACE-Rare (NCT06938542)
- Testing
- Family Centered pediatric palliative care for family caregivers of children with rare diseases.
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Children's National Research Institute
Prader-Willi Syndrome, Aggression
Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS).
- Conditions
- Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes
- Trial name
- PWS-GXR (NCT05657860)
- Testing
- Guanfacine Extended Release
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Maimonides Medical Center
Profound Multiple Intellectual Disabilities
Development of a Visio-behavioral Scale to Evaluate Visual Abilities of Patients With Profound Multiple Intellectual Disabilities (PLH-Vision)
The main objective of this study is to develop and validate a visio-behavioral scale of visual abilities for subjects with profound multiple intellectual disabilities.
- Trial name
- PLH-Vision (NCT03040609)
- Testing
- Visual-behavioral Scale at day 1, Test-retest at the end of 2 weeks, Test at 6 months
- Where
- France
- Volunteers
- 232 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Down Syndrome
Effects of Maze Activities in Down's Syndrome
Down's Syndrome is due to the chromosomal disorder in 47 chromosomes instead of 46, socalled as Trisomy 21. The syndrome has several clinical symptoms including Cardiovascular,neurological, orthopedic, hormonal, cognitive and…
- Trial name
- NCT06234644
- Testing
- Standardized Walking Obstacle Course (SWOC), Conventional Gait Training
- Where
- Pakistan
- Volunteers
- 26 people
- Sponsor
- Riphah International University
Vision Impairment, Hearing Impairment
Health Intervention for Adolescents With Intellectual Disability
People with intellectual disability die five to twenty years earlier than the general population. They also experience high levels of unrecognised disease and receive inadequate levels of health promotion or screening.
- Conditions
- Vision Impairment, Hearing Impairment, Obesity
- Trial name
- Ask (NCT00519311)
- Testing
- Health Intervention Package
- Where
- Australia
- Volunteers
- 732 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Mucopolysaccharidosis I, Mucopolysaccharidosis II
MPS (RaDiCo Cohort) (RaDiCo-MPS)
The goal of this observational study is to characterize the epidemiology and natural history of MPS diseases by building a retrospective and prospective collection of extensive phenotypic data from French MPS patients.
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis III, Mucopolysaccharidosis IV
- Trial name
- NCT06036693
- Where
- 23 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Down Syndrome
Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome
Heterokaryotypic monozygotic twins discordant for Down syndrome (DS) are very rare, with an incidence estimated to be less than 1 over 7,000,000 pregnancy in the general population.
- Trial name
- Colibri (NCT05767216)
- Testing
- Biological sampling
- Where
- France
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Institut Jerome Lejeune
Mucopolysaccharidosis II
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.
- Trial name
- NCT00069641
- Testing
- Iduronate-2-sulfatase enzyme replacement therapy
- Where
- 9 sites in United States, Brazil and 2 more
- Volunteers
- 96 people
- Sponsor
- Shire